We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · January 16, 2021

TKI Dose Reduction and Remission in Patients With CML

British Journal of Haematology


Additional Info

British Journal of Haematology
TKI Dose Reduction Can Effectively Maintain Major Molecular Remission in Patients With Chronic Myeloid Leukaemia
Br. J. Haematol 2020 Dec 24;[EPub Ahead of Print], S Claudiani, JF Apperley, R Szydlo, A Khan, G Nesr, C Hayden, A J Innes, K Dominy, P Foskett, L Foroni, J Khorashad, D Milojkovic

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading